Breast cancer [DS:H00031] Non-small cell lung cancer [DS:H00014] Prostate cancer [DS:H00024] Gastric adenocarcinoma [DS:H00018] Head and neck cancer [DS:H02420]
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CD Taxanes
L01CD02 Docetaxel
D02165 Docetaxel (USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Docetaxel
D02165 Docetaxel (USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
424 Plant extract preparations
4240 Plant extract preparations
D02165 Docetaxel (USP); Docetaxel hydrate (JP18)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00694 Docetaxel
D02165 Docetaxel
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D02165 Docetaxel (USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D02165 Docetaxel hydrate
D02165 Docetaxel injection
D02165 Docetaxel for injection
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02165
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02165
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00694 Docetaxel